Orphan Drug Grant Funding for New Clinical Program!

Submitted by Cumberland Pharma on Tue, 09/24/2019 - 15:00

 

We’ve initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). Based on pre-clinical findings, the U.S. FDA has cleared our application to study ifetroban in DMD patients, 7 years of age and older.

 

Pages